<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC89978</article-id><article-id pub-id-type="pmcid-ver">PMC89978.1</article-id><article-id pub-id-type="pmcaid">89978</article-id><article-id pub-id-type="pmcaiid">89978</article-id><article-id pub-id-type="pmid">10858347</article-id><article-id pub-id-type="doi">10.1128/aac.44.7.1874-1877.2000</article-id><article-id pub-id-type="publisher-id">0795</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Experimental Therapeutics</subject></subj-group></article-categories><title-group><article-title>Efficacies of Sordarin Derivatives <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM211676">GM211676</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> in a Murine Model of Systemic Coccidioidomycosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Clemons</surname><given-names initials="KV">Karl V.</given-names></name><xref ref-type="author-notes" rid="FN150">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stevens</surname><given-names initials="DA">David A.</given-names></name></contrib></contrib-group><aff id="N0x9670ab0.0x9986930">California Institute for Medical Research, San Jose, California 95128; Department of Medicine, Division of Infectious Diseases, Santa Clara Valley Medical Center, San Jose, California 95128; and Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California 94305</aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Division of Infectious Diseases, Santa Clara Valley Medical Center, 751 South Bascom Ave., San Jose, CA 95128-2699. Phone: (408) 998-4557. Fax: (408) 998-2723. E-mail: <email>Karl.Clemons@slip.net</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2000</year></pub-date><volume>44</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">2486</issue-id><fpage>1874</fpage><lpage>1877</lpage><history><date date-type="received"><day>20</day><month>9</month><year>1999</year></date><date date-type="rev-request"><day>23</day><month>1</month><year>2000</year></date><date date-type="accepted"><day>1</day><month>4</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-29 20:25:10.770"><day>29</day><month>04</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac001874.pdf"/><abstract><p>Sordarin derivatives (Glaxo Wellcome) are a new class of compounds that selectively inhibit fungal protein synthesis and have a broad spectrum of activity. Systemic coccidioidomycosis was established in female CD-1 mice infected with <italic>Coccidioides immitis</italic>, and therapy was begun on day 4 with either <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM211676">GM211676</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link>, fluconazole, or no treatment; compounds were given twice daily orally for 19 days at 20 or 100 mg/kg/day. The serum pharmacokinetics of the compounds were studied in uninfected mice. The MICs of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM211676">GM211676</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> for <italic>C. immitis</italic> were 1.56, 0.39, and 0.39 &#956;g/ml, respectively, and the minimum fungicidal concentrations were 6.25, 3.13, and 0.39 &#956;g/ml, respectively. Peak serum levels (sampled at 1 to 2 h) after a single 50-mg/kg dose were 9.8 &#956;g/ml for <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link>, 13 &#956;g/ml for <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM211676">GM211676</ext-link>, and 6.0 &#956;g/ml for <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link>. No accumulation occurred after 19 days of dosing, and peak levels were lower at 3.2 &#956;g/ml for <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM193663">GM193663</ext-link>, 4.0 &#956;g/ml for <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM211676">GM211676</ext-link>, and &lt;2.5 &#956;g/ml for <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link>. We estimate that the <italic>t</italic><sub>1/2</sub> for each compound in serum is &lt;2 h. In vivo, all compounds showed dose-responsive efficacy, significantly prolonging survival over the control groups (100% lethal dose); 80 to 100% of the mice given the 100-mg/kg doses of fluconazole or a GM drug survived. All 100-mg/kg/day regimens were equivalent. At 20 mg/kg/day, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM211676">GM211676</ext-link> was equivalent to 100 mg of fluconazole/kg/day, indicating that <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM211676">GM211676</ext-link> was &#8764;5-fold more efficacious. No mice surviving the 49 days of the experiment were free of infection. All drugs dose responsively reduced the fungal burden in the spleen, liver, and lungs, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GM237354">GM237354</ext-link> at 100 mg/kg/day was superior to all of the other regimens in the reduction of burden in all organs. <italic>C. immitis</italic> was susceptible both in vitro and in vivo to the GM compounds, which were found to be equivalent or superior to fluconazole. These results are encouraging, indicating that further testing in other models of fungal disease is warranted.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>